Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome.


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
04 10 2021
Historique:
received: 10 07 2020
revised: 10 06 2021
accepted: 30 07 2021
entrez: 3 9 2021
pubmed: 4 9 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Gain-of-function mutations in NLRP3 are responsible for a spectrum of autoinflammatory diseases collectively referred to as "cryopyrin-associated periodic syndromes" (CAPS). Treatment of CAPS patients with IL-1-targeted therapies is effective, confirming a central pathogenic role for IL-1β. However, the specific myeloid cell population(s) exhibiting inflammasome activity and sustained IL-1β production in CAPS remains elusive. Previous reports suggested an important role for mast cells (MCs) in this process. Here, we report that, in mice, gain-of-function mutations in Nlrp3 restricted to neutrophils, and to a lesser extent macrophages/dendritic cells, but not MCs, are sufficient to trigger severe CAPS. Furthermore, in patients with clinically established CAPS, we show that skin-infiltrating neutrophils represent a substantial biological source of IL-1β. Together, our data indicate that neutrophils, rather than MCs, can represent the main cellular drivers of CAPS pathology.

Identifiants

pubmed: 34477811
pii: 212620
doi: 10.1084/jem.20201466
pmc: PMC8421266
pii:
doi:

Substances chimiques

IL1B protein, human 0
Interleukin-1beta 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
NLRP3 protein, human 0
Nlrp3 protein, mouse 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : U19 AI104209
Pays : United States
Organisme : European Research Council
ID : ERC-2013-CoG 616050
Pays : International
Organisme : European Research Council
ID : 801823
Pays : International
Organisme : NIAID NIH HHS
ID : R01 AI125567
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR067145
Pays : United States
Organisme : NIAID NIH HHS
ID : K99 AI110645
Pays : United States
Organisme : NIH HHS
ID : K99 AI110645
Pays : United States
Organisme : NIH HHS
ID : R01 AI132494
Pays : United States
Organisme : NIH HHS
ID : R01 DK113592
Pays : United States
Organisme : NIH HHS
ID : R01 AI15586901
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK113592
Pays : United States
Organisme : European Research Council
ID : 802041
Pays : International
Organisme : NIAID NIH HHS
ID : R01 AI132494
Pays : United States

Informations de copyright

© 2021 Stackowicz et al.

Déclaration de conflit d'intérêts

Disclosures: L. Broderick reports "other" from Novartis, Inc. outside the submitted work. H.M. Hoffman reports "other" from Novartis, IFM, AB2Bio, Takeda, and Zomagen; and grants from Jecure outside the submitted work. No other disclosures were reported.

Références

Arthritis Rheum. 2008 Aug;58(8):2443-52
pubmed: 18668535
Arthritis Rheum. 2007 Apr;56(4):1273-1285
pubmed: 17393462
Clin Ther. 2012 Oct;34(10):2091-103
pubmed: 23031624
J Immunol Methods. 2014 Jun;408:89-100
pubmed: 24857755
Blood. 2004 Apr 1;103(7):2809-15
pubmed: 14630794
J Exp Med. 2009 May 11;206(5):1037-46
pubmed: 19364881
J Biol Chem. 2004 May 21;279(21):21924-8
pubmed: 15020601
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2946-51
pubmed: 23382184
J Allergy Clin Immunol. 2016 Jul;138(1):3-14
pubmed: 27373321
Nat Genet. 2001 Nov;29(3):301-5
pubmed: 11687797
J Clin Invest. 2020 Sep 1;130(9):4561-4573
pubmed: 32716363
J Allergy Clin Immunol. 2020 Apr;145(4):1254-1261
pubmed: 31816408
J Exp Med. 2017 May 1;214(5):1249-1258
pubmed: 28385925
Immunity. 2011 Jun 24;34(6):973-84
pubmed: 21703544
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Arthritis Rheum. 2002 Dec;46(12):3340-8
pubmed: 12483741
J Clin Invest. 2013 Nov;123(11):4695-705
pubmed: 24084736
Sci Immunol. 2018 Dec 7;3(30):
pubmed: 30530726
Sci Immunol. 2018 Aug 24;3(26):
pubmed: 30143555
Cell. 2004 Oct 29;119(3):431-43
pubmed: 15507213
Immunity. 2009 Jun 19;30(6):860-74
pubmed: 19501001
Trends Immunol. 2012 Dec;33(12):613-25
pubmed: 23127755
J Immunol. 2008 Sep 15;181(6):3755-9
pubmed: 18768827
J Allergy Clin Immunol. 2017 Aug;140(2):335-348
pubmed: 28780941
Immunity. 2009 Jun 19;30(6):875-87
pubmed: 19501000
N Engl J Med. 2009 Jun 4;360(23):2416-25
pubmed: 19494217
Cell Mol Immunol. 2016 Mar;13(2):148-59
pubmed: 26549800
J Clin Invest. 2017 Dec 1;127(12):4488-4497
pubmed: 29130929
J Clin Invest. 2016 Oct 3;126(10):3981-3998
pubmed: 27643442
Immunity. 2004 Mar;20(3):319-25
pubmed: 15030775
Nat Rev Immunol. 2010 Mar;10(3):210-5
pubmed: 20168318
J Immunol. 1980 Jun;124(6):2728-37
pubmed: 7373045
Nat Immunol. 2008 Oct;9(10):1091-4
pubmed: 18800157
Mol Cell. 2002 Aug;10(2):417-26
pubmed: 12191486
Nat Rev Immunol. 2013 Jun;13(6):397-411
pubmed: 23702978
Lancet. 2004 Nov 13-19;364(9447):1779-85
pubmed: 15541451
Front Pharmacol. 2017 May 22;8:278
pubmed: 28588486
J Allergy Clin Immunol. 2007 Sep;120(3):506-15; quiz 516-7
pubmed: 17765751
Blood. 2011 Dec 22;118(26):6930-8
pubmed: 22001390
Front Cell Infect Microbiol. 2017 Dec 11;7:507
pubmed: 29322034
Immunity. 2012 Jul 27;37(1):85-95
pubmed: 22819042
J Allergy Clin Immunol. 2001 Oct;108(4):615-20
pubmed: 11590390
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):870-5
pubmed: 19139407
Nat Rev Drug Discov. 2020 Apr;19(4):253-275
pubmed: 31969717
Sci Immunol. 2018 Aug 24;3(26):
pubmed: 30143554

Auteurs

Julien Stackowicz (J)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.
Sorbonne Université, Paris, France.

Nicolas Gaudenzio (N)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut national de la santé et de la recherche médicale, UMR 1291, Centre National de la Recherche Scientifique, UMR 5051, University of Toulouse III, Toulouse, France.

Nadine Serhan (N)

Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut national de la santé et de la recherche médicale, UMR 1291, Centre National de la Recherche Scientifique, UMR 5051, University of Toulouse III, Toulouse, France.

Eva Conde (E)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.

Ophélie Godon (O)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.

Thomas Marichal (T)

GIGA-Research and Faculty of Veterinary Medicine, Liège University, Liège, Belgium.

Philipp Starkl (P)

Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Research Laboratory of Infection Biology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Bianca Balbino (B)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.
Sorbonne Université, Paris, France.

Axel Roers (A)

Institute for Immunology, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Dresden, Germany.

Pierre Bruhns (P)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.

Friederike Jönsson (F)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.

Philippe Moguelet (P)

Faculty of Medicine, Sorbonne University, Tenon Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.

Sophie Georgin-Lavialle (S)

Internal Medicine Department, Tenon Hospital, Assistance Publique - Hôpitaux de Paris, Sorbonne University, Paris, France.

Lori Broderick (L)

Division of Pediatric Allergy, Immunology and Rheumatology, University of California, San Diego, and Rady Children's Hospital, San Diego, CA.

Hal M Hoffman (HM)

Division of Pediatric Allergy, Immunology and Rheumatology, University of California, San Diego, and Rady Children's Hospital, San Diego, CA.

Stephen J Galli (SJ)

Department of Pathology, Stanford University School of Medicine, Stanford, CA.
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA.
Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA.

Laurent L Reber (LL)

Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.
Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut national de la santé et de la recherche médicale, UMR 1291, Centre National de la Recherche Scientifique, UMR 5051, University of Toulouse III, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH